German biotech firm BioNTech said on Monday that Sobi's CEO Guido Oelkers will succeed Ugur Sahin as its chief executive.
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (“CEO”), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, “Sobi”), where he has served as CEO since 2017.
BioNTech trades near cash value, implying its advanced oncology pipeline is valued at nearly zero—an opportunity I rate as BUY. BNTX's €16.8B liquidity, $1B buyback, and cost restructuring enable multi-year funding without dilution, reflecting strong management conviction. Key 2026 catalysts include the trastuzumab pamirtecan BLA filing, pivotal Phase 3 oncology readouts, and a binary EPO patent event in September.
Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy profile Shipping will begin soon to ensure rapid access of this season's vaccine NEW YORK and MAINZ, GERMANY, July 29, 2026 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies' 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA) to update COVID-19 vaccines to target the XFG variant of the JN.1 lineage for the 2026-2027 season.
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies' 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medic.
BioNTech's oncology pipeline could help it make a dent in this large and growing market. However, there is one thing investors should consider before initiating a position.
MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
Baader Bank Aktiengesellschaft lowered its stake in BioNTech SE Sponsored ADR (NASDAQ: BNTX) by 10.4% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 136,425 shares of the company's stock after selling 15,914 shares during the period. BioNTech accounts for approximately 0.9% of Baader Bank Aktiengesellschaft's
Amova Asset Management Americas Inc. acquired a new position in shares of BioNTech SE Sponsored ADR (NASDAQ: BNTX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 77,694 shares of the company's stock, valued at approximately $6,905,000. A number of other large investors
On July 8, the Ark Genomic Revolution ETF sold roughly $7.4 million worth of BioNTech stock. Cathie Wood's ETF has now almost completely sold its entire position in BioNTech.
